Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California. The company has 220 employees and generated $23.1 million in revenue. Kura Oncology is dedicated to developing precision medicines for cancer treatment, focusing on small-molecule drug candidates that target specific cancer-driving pathways. Kura Oncology's pipeline comprises three investigational drug candidates: ziftomenib, tipifarnib, and KO-2806. Ziftomenib is designed to inhibit the menin-KMT2A protein-protein interaction and is currently in a Phase 2 trial for patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML). Tipifarnib, a farnesyltransferase inhibitor, is undergoing a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). KO-2806, a next-generation FTI, is set to be evaluated in a Phase 1 trial as both a monotherapy and in combination with other targeted therapies for adult patients with advanced solid tumors. Kura Oncology's approach centers on identifying patients most likely to benefit from treatment by precisely targeting cancer-driving mechanisms. The company aims to develop therapies with significant clinical benefit for patients with high unmet needs in various cancer types. For more information about Kura Oncology and its pipeline, please visit their website at www.kuraoncology.com.